TYP 5.00% 1.9¢ tryptamine therapeutics limited

Where to from here, page-95

  1. Al.
    198 Posts.
    lightbulb Created with Sketch. 114
    The issue is the Ukraine invasion in the short term, this is being seen across biotechs everywhere. For me it’s a signal to find some time and double down on research, because it looks like there will be an amazing 12-18 month buying window for multiple biotechs (I know I won’t actually have time to research ha)
    there is nothing as good as an incentivised founder. Absolutely nothing like it. I work 12-14 hours a day as a business owner and about 7 of those hours is work that an ‘employer’ would never know if it didn’t get done i innately know if I was an employee I wouldn’t be doing the extra work as a wage just couldn’t compensate for what is involved. There’s some data on founder / owner companies outperforming and that this is a factor which funds look for to predict outperformance
    ‘Ultimately Australia is one of the very best places to be for biotech - R&D grant, strong deep & resilient capital markets, and the new ‘patent box’ Australian commercialised patents developed here - 17%
    Last edited by Al.: 04/03/22
 
watchlist Created with Sketch. Add TYP (ASX) to my watchlist
(20min delay)
Last
1.9¢
Change
-0.001(5.00%)
Mkt cap ! $20.69M
Open High Low Value Volume
2.0¢ 2.0¢ 1.9¢ $18.75K 951.1K

Buyers (Bids)

No. Vol. Price($)
2 183839 1.9¢
 

Sellers (Offers)

Price($) Vol. No.
2.0¢ 1000000 1
View Market Depth
Last trade - 11.43am 11/10/2024 (20 minute delay) ?
TYP (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.